Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients

Inclusion Criteria: * Written informed consent of approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial activities. * Histological diagnosis of MSS colorectal adenocarcinoma. * Metastatic disease treated with at least two chemotherapy line, with or without targeted therapies. * Male or female subjects aged ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria. * Lactate dehydrogenase (LDH) levels (\<1.5 ULN) (between 250-450 U/L). Maximum allowed 675 U/L. * Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normality (ULN) and Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver). * Negative serum pregnancy test at screening for women of childbearing potential. * Highly effective contraception for both male and female subjects throughout the study and for at least 60 days after last avelumab treatment administration if the risk of conception exists. * Adequate hematological function: a) Haemoglobin ≥ 9 g/dL (may have been transfused). b) Platelet count ≥ 100 × 109/L. c) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L. * Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (…